home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2948.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
42 lines
Document 2948
DOCN M94A2948
TI VIP and refractory diarrhea in AIDS/ARC patients.
DT 9412
AU Manfredi R; Mastroianni A; Coronado O; Vezzadini P; Fanti MP; Chiodo F;
University of Bologna, Italy.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):188 (abstract no. PB0179). Unique
Identifier : AIDSLINE ICA10/94369627
AB OBJECTIVE. We have previously described 3 AIDS patients (p) with chronic
idiopathic diarrhea associated with elevated vasoactive intestinal
peptide (VIP) secretion (AIDS 1993; 7:223-6). Aim of this study is to
evaluate a series of AIDS/ARC p with intractable infectious and
noninfectious diarrhea. METHODS AND RESULTS. Elevated plasma levels of
VIP (as assessed by a radio-immunoassay) were found in 4/6 p with
prolonged intractable cryptosporidial diarrhea (mean 13.9 +/- 2.2
pmol/l), and in 3/5 p with idiopathic diarrhea (mean 12.8 +/- 4.2
pmol/l), while a control group of 12 AIDS/ARC p without gastrointestinal
disorders showed normal VIP levels (mean 4.4 +/- 2.3 pmol/l; n.v. < 8.8
pmol/l). Six p (3 with infectious diarrhea and 3 with idiopathic
disease) were treated with the somatostatin analogue octreotide (100-300
micrograms/day s.c.) over a mean period of 12.2 +/- 8.7 weeks, showing
remission of the intestinal picture in all pts, associated with a
relevant reduction of plasma VIP concentrations, comparing with
pretreatment values (from a mean level of 11.9 +/- 3.3 to 7.2 +/- 3.5
pmol/l; p < .001, Student t test for paired data). CONCLUSIONS. Both
infectious and non-infectious refractory HIV-related diarrhea show a
frequent association with elevated VIP levels, corrected by octreotide
administration. Assessment of VIP secretion may provide a
pathophysiological rationale for recognizing in advance pts with
intractable diarrhea who may present a better clinical response to
octreotide treatment.
DE Acquired Immunodeficiency Syndrome/*BLOOD/DRUG THERAPY AIDS-Related
Complex/*BLOOD/DRUG THERAPY AIDS-Related Opportunistic
Infections/*BLOOD/DRUG THERAPY Chronic Disease
Cryptosporidiosis/*BLOOD/DRUG THERAPY Diarrhea/*BLOOD/DRUG THERAPY
Human Octreotide/THERAPEUTIC USE Prognosis Treatment Outcome
Vasoactive Intestinal Peptide/*BLOOD MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).